Humasis Co

Humasis Co Equity

The The Equity of Humasis Co (205470.KQ) as of Nov 11, 2026 is 215.06 B KRW. In the previous year, The Equity was 229.26 B KRW — a change of -6.19% (lower).

Equity

215.06 BKRW

YoY

-6.19%

Last updated:

In 2025, Humasis Co's equity was 215.06 B KRW, a -6.19% increase from the 229.26 B KRW equity in the previous year.

The Humasis Co Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
16.13 B KRW
Jan 1, 2019
15.24 B KRW
Jan 1, 2020
48.84 B KRW
Jan 1, 2021
202.01 B KRW
Jan 1, 2022
346.73 B KRW
Jan 1, 2023
287.33 B KRW
Jan 1, 2024
229.26 B KRW
Jan 1, 2025
215.06 B KRW
The Humasis Co Equity history
YEAREquityYoY
215.06 BKRW-6.19%
229.26 BKRW-20.21%
287.33 BKRW-17.13%
346.73 BKRW+71.65%
202.01 BKRW+313.60%
48.84 BKRW+220.39%
15.24 BKRW-5.47%
16.13 BKRW+3.40%
15.60 BKRW+43.58%
10.86 BKRW-48.85%
21.23 BKRW+1.31%
20.96 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Humasis Co's Equity

Humasis Co's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Humasis Co's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Humasis Co's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Humasis Co's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Humasis Co’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Humasis Co stock

The Equity of Humasis Co is 215.06 B KRW in 2025.

The Equity of Humasis Co changed from 229.26 B KRW to 215.06 B KRW, representing a -6.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Humasis Co since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Humasis Co

All Key Metrics — Humasis Co